Sugi Predict

Sugi Predict / Compounds / SCHEMBL335779

SCHEMBL335779

SCHEMBL335779

COC(=O)Cc1cccc(CBr)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.59
▸ ALDH1A1 P00352 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ HSP90AB1 P08238 1/20 0.50
▸ CYP4F2 P78329 2/20 0.49
▸ CYP4A11 Q02928 2/20 0.49
▸ HPGD P15428 3/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12400239 0.91 SLC7A5 (0.68) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL27649231 0.86 SLC7A5 (0.56) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL4394735 0.85 SLC7A5 (0.62) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL14115300 0.85 HSP90AB1 (0.62) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL13461093 0.84 CYP4F2 (0.52) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL1560308 0.84 SLC7A5 (0.65) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL694460 0.84 SLC7A5 (0.65) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL12508635 0.84 SLC7A5 (0.60) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL7718934 0.84 SLC7A5 (0.60) SLC7A5ALDH1A1GAAGFERHSP90AB1
SCHEMBL15504971 0.83 SIRT2 (0.51) SLC7A5ALDH1A1CYP4F2CYP4A11KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2026-03-24 — — US disclosed
EP-4526298-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS F. Hoffmann-La Roche AG (CH) 2025-03-26 — — EP disclosed
WO-2025059562-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME ATAVISTIK BIO, INC. (US) 2025-03-20 — — WO disclosed
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS HOFFMANN-LA ROCHE INC. (US) 2025-03-06 — — US disclosed
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS PHEON THERAPEUTICS LTD (GB) 2025-01-09 — — US disclosed
US-20240279220-A1 INDOLE COMPOUNDS AND METHODS OF USE SIONNA THERAPEUTICS INC. 2024-08-22 — — US disclosed
EP-4396179-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION (US) 2024-07-10 — — EP disclosed
CN-118201919-A Indole compounds and methods of use 健赞公司 2024-06-14 — — CN disclosed
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines PHEON THERAPEUTICS LTD (GB) 2024-02-27 — — US disclosed
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS PHEON THERAPEUTICS LTD (GB) 2024-01-04 — — US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 — — EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 — — EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
EP-0481676-B1 Hydroxyquinolone derivatives MERCK SHARP & DOHME (GB) 1997-01-29 — — EP disclosed
EP-0386839-B1 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME (GB) 1997-01-15 — — EP disclosed
US-5559125-A NMDA AND AMPA RECEPTOR ANTAGONISTS, SCHIZOPHRENIA MERCK, SHARP & DOHME LIMITED (GB) 1996-09-24 — — US disclosed
US-5348962-A Nervous system disorders; schizophrenia MERCK SHARPE & DOHME LTD. 1994-09-20 — — US disclosed
US-5231102-A Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME, LTD. (GB) 1993-07-27 — — US disclosed
EP-0481676-A1 Hydroxyquinolone derivatives MERCK SHARP & DOHME LTD. (GB) 1992-04-22 — — EP disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279220-A1 INDOLE COMPOUNDS AND METHODS OF USE CFTR, INMT, IDO1 SLC7A5 208/4885ALDH1A1 784/4885GAA 1144/4885
US-12583857-B2 Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines CNR1, MTNR1B, MTNR1A SLC7A5 1593/4885ALDH1A1 1463/4885GAA 3302/4885
US-20250011317-A1 ANTI-PROLIFERATIVE AGENTS CCND2, BRD2, CCND3 SLC7A5 1033/4885ALDH1A1 3182/4885GAA 1519/4885
US-20240002379-A1 ASYMMETRIC CONJUGATE COMPOUNDS TUBA1C, MTX2, CCNO SLC7A5 327/4885ALDH1A1 2285/4885GAA 3535/4885
US-20250074913-A1 PYRAZOLE DERIVATIVES AS STING AGONISTS STING1, CGAS, MAVS SLC7A5 2743/4885ALDH1A1 4593/4885GAA 3157/4885
US-11912700-B2 Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines MKI67, CCND2, CCND1 SLC7A5 2589/4885ALDH1A1 443/4885GAA 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.